Abstract:Since ancient times it is known that melancholia and sleep disturbances co-occur. The introduction of polysomnography into psychiatric research confirmed a disturbance of sleep continuity in patients with depression, revealing not only a decrease in Slow Wave Sleep, but also a disinhibition of REM (rapid eye movement) sleep, demonstrated as a shortening of REM latency, an increase of REM density, as well as total REM sleep time. Initial hopes that these abnormalities of REM sleep may serve as differential-diagnostic markers for subtypes of depression were not fulfilled. Almost all antidepressant agents suppress REM sleep and a time-and-dose–response relationship between total REM sleep suppression and therapeutic response to treatment seemed apparent. The so-called Cholinergic REM Induction Test revealed that REM sleep abnormalities can be mimicked by administration of cholinomimetic agents. Another important research avenue is the study of chrono-medical timing of sleep deprivation and light exposure for their positive effects on mood in depression. Present day research takes the view on insomnia, i.e., prolonged sleep latency, problems to maintain sleep, and early morning awakening, as a transdiagnostic symptom for many mental disorders, being most closely related to depression. Studying insomnia from different angles as a transdiagnostic phenotype has opened many new perspectives for research into mechanisms but also for clinical practice. Thus, the question is: can the early and adequate treatment of insomnia prevent depression? This article will link current understanding about sleep regulatory mechanisms with knowledge about changes in physiology due to depression. The review aims to draw the attention to current and future strategies in research and clinical practice to the benefits of sleep and depression therapeutics.

Microglia in the Pathogenesis of Depression, Insomnia and Their Comorbidity

Microglia Sing the Prelude of Neuroinflammation-Associated Depression

Microglia in depression: current perspectives

Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression

Common Cellular and Molecular Mechanisms and Interactions Between Microglial Activation and Aberrant Neuroplasticity in Depression

Prospective Role of MicroRNAs in Depression

Microglial NLRP3 inflammasome-mediated neuroinflammation and therapeutic strategies in depression

Microglial Regulation of Sleep and Wakefulness

Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics

Microglial Glutaminase 1 Deficiency Mitigates Neuroinflammation Associated Depression.

Sleep, insomnia, and depression

Understanding neuron-glia crosstalk and biological clocks in insomnia

Mechanisms of Inhibition of Excessive Microglial Activation by Melatonin.

Shared microglial mechanisms underpinning depression and chronic fatigue syndrome and their comorbidities

Navigating the Complex Terrain of Dysregulated Microglial Function in Depressive Disorders: Insights, Challenges and Future Directions

Sleep Disturbances and Depression Are Co-morbid Conditions: Insights from Animal Models, Especially Non-human Primate Model

Microglia and Sleep Disorders

Stress induced microglial activation contributes to depression

A novel two-hit insomnia and inflammation rodent model of depressive-like behaviors

Noteworthy perspectives on microglia in neuropsychiatric disorders

Microbiome-Based Therapeutics for Insomnia